An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology

Cancer Research

Volumn 64, Issue 6, 2004, Pages 2251-2257

  Zhu, Yong ^a,b   Spitz, Margaret R ^a   Amos, Christopher I ^a   Lin, Jie ^a   Schabath, Matthew B ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; DNA REPAIR; EPIDEMIOLOGICAL DATA; GENETIC CONSERVATION; GENOTYPE; HUMAN; HUMAN GENOME; POPULATION RESEARCH; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES DIFFERENCE;

ALLELES; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; EPIDEMIOLOGY, MOLECULAR; EVOLUTION, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOTYPE; HUMANS; MASS SCREENING; NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 1542405868     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2800     Document Type: Article

References (136)

1. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999;22:231-8.
2. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436-46.
3. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci USA 2003;100:1151-6.
4. Ronen A, Glickman BW. Human DNA repair genes. Environ Mol Mutagen 2001; 37:241-83.
5. Matsuo K, Hamajima N, Shinoda M, et al. Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis (Lond.) 2001;22:913-6.
6. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomark Prev 2001;10:209-16.
7. Gryfe R, Di Nicola N, Lal G, Gallinger S, Redston M. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 1999;64: 378-84.
8. Park JY, Muscat JE, Ren Q, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk Cancer Epidemiol Biomark Prev 1997;6:791-7.
9. Takezaki T, Hamajima N, Matsuo K, et al. Association of polymorphisms in the β-2 and β-3 adrenoceptor genes with risk of colorectal cancer in Japanese. Int J Clin Oncol 2001;6:117-22.
10. Murata M, Watanabe M, Yamanaka M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001;165:171-7.
11. Huang XE, Hamajima N, Saito T, et al. Possible association of β2- and β3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer. Breast Cancer Res 2001;3:264-9.
12. London SJ, Daly AK, Fairbrother KS, et al. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res 1995;55:6035-7.
13. Aktas D, Guney I, Alikasifoglu M, et al. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 2002;86:124-8.
14. Miyoshi Y, Takahashi Y, Egawa C, Noguchi S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J 2002;8:209-15.
15. Ishitobi M, Miyoshi Y, Ando A, et al. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin Cancer Res 2003;9:1376-80.
16. Wang AH, Sun CS, Li LS, Huang JY, Chen QS. Relationship of tobacco smoking CYP1A1 GSTM1 gene polymorphism and esophageal cancer in Xi'an. World J Gastroenterol 2002;8:49-53.
17. Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer 2003;103:427-30.
18. McWilliams JE, Evans AJ, Beer TM, et al. Genetic polymorphisms in head and neck cancer risk. Head Neck 2000;22:609-17.
19. Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomark Prev 2002;11:413-6.
20. Basham VM, Pharoah PD, Healey CS, et al. Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk. Carcinogenesis (Lond.) 2001;22: 1797-800.
21. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis (Lond.) 1997;18:2307-11.
22. Bergman-Jungestrom M, Wingren S. Catechol-O-methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer 2001;85: 859-62.
23. Hung RJ, Boffetta P, Brockmoller J, et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis (Lond.) 2003;24:875-82.
24. Hamajima N, Matsuo K, Tajima K, et al. Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol 2001;6:13-8.
25. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 2002;11: 489-92.
26. Yim DS, Parkb SK, Yoo KY, et al. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 2001; 11:279-86.
27. Zheng W, Xie DW, Jin F, et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomark Prev 2000;9:147-50.
28. Garner EI, Stokes EE, Berkowitz RS, Mok SC, Cramer DW. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002;62:3058-62.
29. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-6.
30. Goodman JE, Lavigne JA, Hengstler JG, et al. Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiol Biomark Prev 2000;9:1373-6.
31. Wedren S, Rudqvist TR, Granath F, et al. Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis (Lond.) 2003;24:681-7.
32. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996;6:527-33.
33. Severi G, Giles GG, Southey MC, et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst (Bethesda) 2003;95: 818-24.
34. Lin HJ, Lakkides KM, Keku TO, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomark Prev 2002;11:1305-15.
35. Moysich KB, Shields PG, Freudenheim JL, et al. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomark Prev 1999;8:41-4.
36. Iughetti P, Suzuki O, Godoi PH, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001;61:7375-8.
37. Hamada GS, Sugimura H, Suzuki I, et al. The heme-binding region polymorphism of cytochrome P4501A1 (Cyp1A1), rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol Biomark Prev 1995;4:63-7.
38. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998;58:5291-3.
39. Sugimura H, Wakai K, Genka K, et al. Association of Ile462Val (exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomark Prev 1998;7:413-7.
40. London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 2000;28:147-55.
41. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer 1999;80:1838-43.
42. Spurdle AB, Purdie DM, Webb PM, et al. The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. Mol Carcinog 2001;30:71-8.
43. Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomark Prev. 2000;9:185-91.
44. Lancaster JM, Brownlee HA, Bell DA, et al. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 1996;17:160-2.
45. Song N, Tan W, Xing D, Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis (Lond.) 2001;22:11-6.
46. To-Figueras J, Gene M, Gomez-Catalan J, et al. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett 2001;173:155-62.
47. London SJ, Yuan JM, Coetzee GA, et al. CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. Cancer Epidemiol Biomark Prev 2000;9:987-91.
48. Harrison DJ, Hubbard AL, MacMillan J, Wyllie AH, Smith CA. Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 1999;79:168-71.
49. Setiawan VW, Zhang ZF, Yu GP, et al. GSTP1 polymorphisms and gastric cancer in a high-risk Chinese population. Cancer Causes Control 2001;12:673-81.
50. Baxter SW, Choong DY, Campbell IG. Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer. Cancer Lett 2002;177:75-81.
51. Zhao H, Spitz MR, Gwyn KM, Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog 2002;33:99-104.
52. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 1994;72:240-8.
53. Ulrich CM, Bigler J, Whitton JA, Bostick R, Fosdick L, Potter JD. Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomark Prev 2001;10:875-82.
54. Tiemersma EW, Omer RE, Bunschoten A, et al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomark Prev 2001;10:785-91.
55. Xing DY, Tan W, Song N, Lin DX. Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 2001;95:140-3.
56. Le Marchand L, Donlon T, Lum-Jones A, Seifried A, Wilkens LR. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol Biomark Prev 2002;11:409-12.
57. Sugimura H, Kohno T, Wakai K, et al. hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomark Prev 1999;8:669-74.
58. Choi JY, Hamajima N, Tajima K, et al. hOGG1 Ser326Cys polymorphism and breast cancer risk among Asian women. Breast Cancer Res Treat 2003;79:59-62.
59. Takezaki T, Gao CM, Wu JZ, et al. hOGG1 Ser(326)Cys polymorphism and modification by environmental factors of stomach cancer risk in Chinese. Int J Cancer 2002;99:624-7.
60. Xing D, Tan W, Song N, Lin D. Genetic polymorphism in hOGG1 and susceptibility to esophageal cancer [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2000;17:377-80.
61. Ito H, Hamajima N, Takezaki T, et al. A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol 2002;12:258-65.
62. Hanaoka T, Sugimura H, Nagura K, et al. hOGG1 exon7 polymorphism and gastric cancer in case-control studies of Japanese Brazilians and non-Japanese Brazilians. Cancer Lett 2001;170:53-61.
63. Goodman MT, Wu AH, Tung KH, et al. Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer. Am J Epidemiol 2002;156:693-701.
64. Cozen W, Peters R, Reichardt JK, et al. Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control 2002;13: 113-20.
65. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002;62:1784-9.
66. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC. GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk. Cancer Lett 2002;180:165-71.
67. Margiotti K, Kim E, Pearce CL, Spera E, Novelli G, Reichardt JK. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002;53:65-8.
68. Shepard TF, Platz EA, Kantoff PW, et al. No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study. Cancer Epidemiol Biomark Prev 2000;9:1267-8.
69. Kim JW, Roh JW, Park NH, et al. Interferon, α17 (IFNA17) Ile184Arg polymorphism and cervical cancer risk. Cancer Lett 2003;189:183-8.
70. Zhao M, Lewis R, Gustafson DR, et al. No apparent association of GSTP1 A(313)G polymorphism with breast cancer risk among postmenopausal Iowa women. Cancer Epidemiol Biomark Prev 2001;10:1301-2.
71. Wang W, Xue S, Ingles SA, et al. An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas. Cancer Epidemiol Biomark Prev 2001;10:931-6.
72. Yamamura K, Kiyohara C, Nakanishi Y, Takayama K, Hara N. Lung cancer risk and genetic polymorphism at the glutathione S-transferase P1 locus in male Japanese [in Japanese]. Fukuoka Igaku Zasshi 2000;91:203-6.
73. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomark Prev 2000;9:339-42.
74. Jeronimo C, Varzim G, Henrique R, et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomark Prev 2002;11:445-50.
75. Mitrunen K, Sillanpaa P, Kataja V, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis (Lond.) 2001;22:827-9.
76. Wang LI, Miller DP, Sai Y, et al. Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst (Bethesda) 2001;93:1818-21.
77. Ulrich CM, Kampman E, Bigler J, et al. Lack of association between the C677T MTHFR polymorphism and colorectal hyperplastic polyps. Cancer Epidemiol Biomark Prev 2000;9:427-33.
78. To-Figueras J, Gene M, Gomez-Catalan J, et al. Genetic polymorphism of glutathione S-transferase P1 gene and lung cancer risk. Cancer Causes Control 1999;10: 65-70.
79. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
80. Helzlsouer KJ, Selmin O, Huang HY, et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst (Bethesda) 1998;90:512-8.
81. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4.
82. Campbell IG, Baxter SW, Eccles DM, Choong DY. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 2002;4:1-4.
83. Wang Y, Spitz MR, Schabath MB, et al. Association between glutathione S-transferase P1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer 2003;40:25-32.
84. Miao X, Xing D, Tan W, et al. Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at-risk Chinese population. Cancer Epidemiol Biomark Prev 2002;11:1454-8.
85. Shen H, Xu Y, Zheng Y, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer 2001;95:332-6.
86. Marugame T, Tsuji E, Inoue H, et al. Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. Cancer Lett 2000;151:181-6.
87. Xie D, Shu XO, Deng Z, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (Bethesda) 2000;92:412-7.
88. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomark Prev 1997;6:87-92.
89. Wang L, Habuchi T, Takahashi T, et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer 2002;97: 787-90.
90. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003;536:131-7.
91. Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A. Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 2001;173:37-41.
92. Sjalander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis (Lond.) 1996;17:1313-6.
93. Ratnasinghe D, Tangrea JA, Andersen MR, et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000;60:6381-3.
94. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;179:175-83.
95. Sjalander A, Birgander R, Rannug A, et al. Association between the p21 codon 31 A1 (Arg) allele and lung cancer. Hum Hered 1996;46:221-5.
96. Xing D, Qi J, Tan W, et al. Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003;20:35-8.
97. Henner WD, Evans AJ, Hough KM, et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001;49:263-6.
98. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
99. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 2000;9:1037-42.
100. David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 2001;10:911-2.
101. Biros E, Kalina I, Biros I, et al. Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma 2001;48:407-11.
102. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis (Lond.) 2000;21:2219-23.
103. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30.
104. Park JY, Lee SY, Jeon HS, et al. Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer 2002;36:15-6.
105. Pierce LM, Sivaraman L, Chang W, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomark Prev 2000;9:1199-204.
106. Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomark Prev 2002;11:1004-11.
107. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis (Lond.) 2002;23: 1321-5.
108. Tenti P, Vesentini N, Rondo Spaudo M, et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomark Prev 2000;9:435-8.
109. Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. Cancer Lett 2002;178:181-6.
110. Madeleine MM, Shera K, Schwartz SM, et al. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomark Prev 2000;9:225-7.
111. Shen H, Xu Y, Qian Y, et al. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer 2000;88:601-6.
112. Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst (Bethesda) 2003;95:812-8.
113. Ratnasinghe D, Yao SX, Tangrea JA, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomark Prev 2001;10:119-23.
114. Kerridge I, Lincz L, Scorgie F, et al. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;118:477-81.
115. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomark Prev 2001; 10: 125-31.
116. Paltoo D, Woodson K, Taylor P, et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Lett 2003;191:67-74.
117. Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor γ gene with breast cancer and body mass. Pharmacogenetics 2002;12: 597-603.
118. Abdel-Rahman SZ, Soliman AS, Bondy ML, et al. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett 2000;159:79-86.
119. Spurdle AB, Hopper JL, Chen X, et al. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomark Prev 2002;11:439-43.
120. Spurdle AB, Webb PM, Purdie DM, et al. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis (Lond.) 2001;22:717-21.
121. Febbo PG, Kantoff PW, Platz EA, et al. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999;59:5878-81.
122. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-α reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001;57: 199-204.
123. Park JY, Lee SY, Jeon HS, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomark Prev 2002;11:23-7.
124. Pearce CL, Makridakis NM, Ross RK, et al. Steroid 5-α reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomark Prev 2002;11:417-8.
125. Li Z, Habuchi T, Mitsumori K, et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 2003;169: 2378-81.
126. Wang Y, Spitz MR, Tsou AM, et al. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 2002; 35:137-42.
127. Zheng W, Xie D, Cerhan JR, et al. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomark Prev 2001;10:89-94.
128. Nelson HH, Kelsey KT, Mott LA, Karagas MR. The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 2002;62:152-5.
129. Wu MT, Wang YT, Ho CK, et al. SULT1A1 polymorphism and esophageal cancer in males. Int J Cancer 2003;103:101-4.
130. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29→C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. JAMA 2001;285: 2859-63.
131. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomark Prev 2003;12:359-65.
132. MacLeod SL, Nowell S, Plaxco J, Lang NP. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000;7:777-82.
133. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001;461:273-8.
134. Gsur A, Preyer M, Haidinger G, et al. A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomark Prev 2002;11:497-8.
135. Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis (Lond.) 2001;22:593-7.
136. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomark Prev 2002;11:939-43.